



# The Peak Registry

A Global Longitudinal Study of PK Deficiency

SPONSORED BY AGIOS PHARMACEUTICALS

## ***An Unwavering Commitment to Patients with Pyruvate Kinase Deficiency***

Introducing a new study dedicated to  
advancing knowledge of:

- Natural history
- Disease burden
- Patient/caregiver-reported outcomes
- Current treatment and outcomes

## ***The Peak Registry is a global longitudinal study of patients diagnosed with pyruvate kinase deficiency***

Participation in the Peak Registry benefits the community of patients and practitioners seeking information about disease burden, treatment outcomes and best clinical practices. Benefits may include:

- Increased awareness among patients and practitioners of the signs, symptoms and diagnosis of PK deficiency
- Knowledge of current supportive care options and opportunities to better manage the challenges faced by patients with PK deficiency
- Collaboration with practitioners around the globe who are dedicated to their patients with PK deficiency
- Access to regular study summaries and updates
- Opportunity to contribute to the medical discourse around PK deficiency



**To learn more about the Peak Registry, please visit  
[PeakRegistry.com](https://PeakRegistry.com) or email [peakregistry@agios.com](mailto:peakregistry@agios.com)**